Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Depreciation and Depletion: 2019-2023

Historic Depreciation and Depletion for Benitec Biopharma (BNTC) over the last 3 years, with Sep 2023 value amounting to $19,000.

  • Benitec Biopharma's Depreciation and Depletion fell 54.76% to $19,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $121,000, marking a year-over-year decrease of 22.93%. This contributed to the annual value of $167,000 for FY2022, which is 27.71% down from last year.
  • Per Benitec Biopharma's latest filing, its Depreciation and Depletion stood at $19,000 for Q3 2023, which was down 54.76% from $42,000 recorded in Q3 2022.
  • Benitec Biopharma's 5-year Depreciation and Depletion high stood at $67,000 for Q4 2020, and its period low was $6,000 during Q2 2022.
  • Its 3-year average for Depreciation and Depletion is $43,375, with a median of $52,000 in 2021.
  • Per our database at Business Quant, Benitec Biopharma's Depreciation and Depletion soared by 39.58% in 2021 and then tumbled by 88.46% in 2022.
  • Over the past 5 years, Benitec Biopharma's Depreciation and Depletion (Quarterly) stood at $51,000 in 2019, then spiked by 31.37% to $67,000 in 2020, then declined by 17.91% to $55,000 in 2021, then decreased by 19.23% to $42,000 in 2022, then plummeted by 54.76% to $19,000 in 2023.
  • Its Depreciation and Depletion stands at $19,000 for Q3 2023, versus $42,000 for Q3 2022 and $6,000 for Q2 2022.